title: Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin.
abstract: OBJECTIVE
  To investigate whether silencing Fas-associated phosphatase 1 (FAP-1) expression enhances the efficiency of chemotherapy for colon carcinoma with oxaliplatin.
  
  
  METHODS
  Expression of FAP-1 in mRNA and protein was detected by reverse transcription polymerase chain reaction (RT-PCR) and flow cytometry. Small interfering RNA (siRNA) was designed according to the FAP-1 mRNA sequence. Cell proliferation was evaluated by methyl thiazolyl tetrazolium (MTT) assay. Anenxin V- and propidine iodine (PI) were assayed by flow cytometry for the detection of apoptosis.
  
  
  RESULTS
  The expression of FAP-1 was increased in SW480 cells after chemotherapy with oxaliplatin. Transfection of FAP-1 siRNA into SW480 cells silenced the expression of FAP-1 and consequently abolished the inhibitory function of Fas/FasL-mediated apoptosis pathway, thus increasing the efficacy of chemotherapy for colon carcinoma with oxaliplatin.
  
  
  CONCLUSIONS
  RNA interference combined with conventional chemotherapy is more effective against colon cancer.
authors.affiliation: Department of Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China.
authors.forename: Zhi-Yu
authors.initials: ZY
authors.lastname: Xiao
authors.forename: Wei
authors.initials: W
authors.lastname: Wu
authors.forename: Navada
authors.initials: N
authors.lastname: Eagleton
authors.forename: Huan-Qing
authors.initials: HQ
authors.lastname: Chen
authors.forename: Jing
authors.initials: J
authors.lastname: Shao
authors.forename: Hong
authors.initials: H
authors.lastname: Teng
authors.forename: Tian-Hao
authors.initials: TH
authors.lastname: Liu
authors.forename: Zhi-Min
authors.initials: ZM
authors.lastname: Jiang
authors.forename: He-Rui
authors.initials: HR
authors.lastname: Yao
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009944:Organoplatinum Compounds / Q000494:pharmacology*; D000077150:Oxaliplatin; D054595:Protein Tyrosine Phosphatase, Non-Receptor Type 13 / Q000235:genetics* / Q000378:metabolism; D034622:RNA Interference; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014162:Transfection
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D000077150:Oxaliplatin; C516742:PTPN13 protein, human; D054595:Protein Tyrosine Phosphatase, Non-Receptor Type 13